Eden Biodesign and Selexis SA Announce Continued Cooperation and a Global Joint-Marketing Collaboration

LIVERPOOL, U.K. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Eden Biodesign Ltd. and Selexis SA today jointly announced their continued collaboration via a joint-marketing partnership, which will provide global biopharmaceutical companies easy access to their highly complementary services, and the opportunity to drastically reduce timelines and risk for development of monoclonal antibodies and recombinant proteins derived from mammalian cell culture.